Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Pembrolizumab in PD-L1+ treatment-naïve NSCLC
NCT04164745Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04164745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164745.